Elective Adhesiolysis vs. a Wait-and-see Policy to Prevent Recurrences After Conservative Treatment of Adhesive Small Bowel Obstruction
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Jan 10, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different approaches to prevent recurring adhesive small bowel obstruction (aSBO) in patients who have recently recovered from this condition. aSBO occurs when scar tissue from previous surgeries or injuries causes the intestines to stick together, leading to blockages. The trial will compare elective adhesiolysis, a surgical procedure that removes these adhesions, with a wait-and-see approach, which is the current standard treatment. The goal is to see if the surgical option can significantly reduce the chance of future blockages and improve patients' quality of life.
To participate in this trial, you need to be an adult aged 18 or older who has recently recovered from aSBO through conservative treatment, meaning without surgery. You should not have serious medical issues that would make surgery unsafe, and you must meet certain imaging criteria to confirm the cause of your obstruction. If you join the study, you can expect to either undergo the adhesiolysis procedure or follow the wait-and-see method, and researchers will track your health outcomes over time. This trial aims to provide insights that could help improve care for patients with this common and challenging condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients aged 18 years and older who have recently recovered from aSBO by small bowel obstruction managed by conservative treatment.
- • Patients who have previously been operated (high a prior risk of adhesions) are required to have no signs of other causes of bowel obstruction on imaging studies (CT-scan).
- • Patients with no previous operation in history (low a prior risk of adhesions) are required to have typical signs for aSBO on imaging studies (abrupt change of bowel calibre, closed loop, or signs of torsion on vessels in the mesentery on CT-scan).
- Exclusion Criteria:
- • Patient who are unfit for reoperation for surgical, anesthesiological or medical reasons as determined by multidisciplinary team assessment or pre-operative screening
- • Patients with active malignancy, reducing life expectancy
- • Pregnancy
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Antwerpen, , Belgium
Almelo, , Netherlands
Nijmegen, , Netherlands
Amsterdam, , Netherlands
Roermond, , Netherlands
Brussles, , Belgium
Leuven, , Belgium
Sint Niklaas, , Belgium
Boxmeer, , Netherlands
Harderwijk, , Netherlands
Maastricht, , Netherlands
Rotterdam, , Netherlands
Venlo, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported